Medscape7m
Oral GLP-1 Receptor Agonist Reduces CV Risk
Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...
Managed Healthcare Executive9h
GLP-1 Receptor Agonists Offer Less Invasive Alternative to Bariatric Surgery for CV Health in Obese Patients | ACC 2025
Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.
MedPage Today10h
GLP-1 Spending Hit $5.8 Billion in 2022 for U.S. Adults Without Diabetes
The prevalence of U.S. adults without diabetes who filled a GLP-1 receptor agonist prescription rose from 0.1% in 2018 to 0.4 ...
Physician's Weekly20h
Optimized Prescribing of SGLT2 Inhibitors and GLP-1 RAs in High-Risk Patients
The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...